<DOC>
	<DOC>NCT00256854</DOC>
	<brief_summary>This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.</brief_summary>
	<brief_title>Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Diagnosis of RLS using IRLS Study Group (IRLSSG) diagnostic criteria. Subjects currently being treated for RLS with a stable dose (for at least 2 weeks) of ropinirole IR given once daily. Subjects with RLS symptoms during both the evening and night or night time only. Subjects who have given written informed consent to participate. Subjects who require treatment of daytime RLS symptoms. Signs of secondary RLS, serum ferritin level less than 10 mcg/L. Movement Disorders, Clinically significant or unstable medical conditions. Abnormal labs, electrocardiogram (ECG) or physical findings. Receiving prohibited medications. Sleeping habits incompatible with study design. Intolerance to ropinirole or other dopamine agonist. Pregnant or lactating. Women of childbearing potential who are not practicing an acceptable method of birth control.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>RLS</keyword>
	<keyword>Ropinirole</keyword>
	<keyword>Restless Legs Syndrome</keyword>
</DOC>